Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy
Gema Mateo(Complejo Hospitalario de Salamanca), Jesús F. San Miguel(Clinica Universidad de Navarra), Juan José Lahuerta(Research Institute Hospital 12 de Octubre), María‐Victoria Mateos(Hospital Clínico San Carlos), María-Ángeles Montalbán(Research Institute Hospital 12 de Octubre), Javier de la Rubia(Universitat de València), José M. Ojanguren(Hospital de Galdakao), Norma C. Gutiérrez(Universidad de Salamanca), María José Terol(Hospital Clínico Universitario de Valencia), María‐Belén Vídriales(Complejo Hospitalario de Salamanca), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Luis Palomera(BioCruces Health research Institute), Josep‐María Ribera(Universitat Autònoma de Barcelona), Alberto Órfão(Universidad de Salamanca), Laura Montejano(Hospital Universitario 12 De Octubre), Joan Bladé(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joaquín Diaz‐Mediavilla(Hospital Clínico San Carlos), Laura Rosiñol(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Rafael Martínez(Hospital Clínico San Carlos), Felipe de Arriba(Hospital General Universitario Morales Meseguer)
Cited by 210
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k